{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:11:29Z","timestamp":1776057089218,"version":"3.50.1"},"reference-count":49,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Municipal Health Commission Health industry clinical research project","award":["ZXQ005"],"award-info":[{"award-number":["ZXQ005"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102406"],"award-info":[{"award-number":["82102406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204502"],"award-info":[{"award-number":["82204502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hangzhou medical health technology project","award":["B20232013"],"award-info":[{"award-number":["B20232013"]}]},{"name":"Professional Technical Service Platform for Comprehensive Preclinical Pharmacodynamic Evaluation and Clinical Translation of Antibacterial Agents","award":["23DZ2291200"],"award-info":[{"award-number":["23DZ2291200"]}]},{"name":"the Shanghai Pujiang Programme","award":["No. 23PJD016"],"award-info":[{"award-number":["No. 23PJD016"]}]},{"name":"The Three-year Action Plan Project for Public Health from Shanghai Municipal Health","award":["GWVI-11.2-YQ03"],"award-info":[{"award-number":["GWVI-11.2-YQ03"]}]},{"name":"Major Project of Guangzhou National Laboratory","award":["No.GZNL2024A01030"],"award-info":[{"award-number":["No.GZNL2024A01030"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>High-dose rifamycin (HDR) regimens have demonstrated significant potential in tuberculosis (TB) treatment. This study aims to evaluate the efficacy and safety profile of different HDR regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Using a systematic review and Bayesian network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>PubMed, Web of Science, Cochrane Library and Embase were searched up to 2 November 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>Randomised controlled trials that compared the efficacy and safety of HDR regimens (rifampin 15\u201330\u2009mg\/kg\/day and rifapentine 7.5\u201320\u2009mg\/kg\/day) to standard-dose rifampin in patients with pulmonary drug-susceptible TB were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>The risk of bias was assessed using Cochrane tools. We conducted NMA with GEMTC in R. The simulation was performed using the Markov Chain Monte Carlo technique set on four parallel chains, with 20\u2009000 burn-in iterations, 50\u2009000 inference iterations and a thinning factor of n=2.5. To check for model convergence, Gelman and Rubin diagnostic plots and density plots were applied. We assessed heterogeneity using the I\u00b2 test, evaluated transitivity by comparing effect modifiers across studies and examined consistency via node-splitting analysis. The confidence in network meta-analysis online tool and Cochrane Risk of Bias 2.0 Tool were used to assess evidence certainty and risk of bias, respectively. Higher surface area under the cumulative rank curve scores indicated a higher probability of top-ranking treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 15\u2009766 citations screened, 15 randomised controlled trials were included, encompassing 6456 subjects. The risk of bias was low in 14 studies, with some concerns in one. Patients receiving rifapentine 20\u2009mg\/kg\/day (risk ratio, 1.09; 95% credible interval, 1.03 to 1.17) had higher culture conversion rates at 8 weeks in solid culture compared with the control. There was no significant difference in primary efficacy within all HDR regimens. Rifapentine 20\u2009mg\/kg\/day was ranked as the most effective intervention for primary efficacy. No statistical difference in the incidence of serious adverse events was found between all regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rifapentine 20 mg\/kg\/day may be the most effective for achieving the strongest anti-TB activity. All HDR regimens demonstrated good safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024504575.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097912","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T01:40:32Z","timestamp":1759714832000},"page":"e097912","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: a Bayesian network meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-413X","authenticated-orcid":false,"given":"Zhen","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailan","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis Internal Medicine II, Hunan Province Chest Hospital, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The First People's Hospital of Linping District, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, The First People's Hospital of Linping District, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijia","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Shanghai Sci-Tech Inno Center for Infection & Immunity, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China"},{"name":"Key Laboratory of Clinical Pharmacology of Antibiotics, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Shanghai Sci-Tech Inno Center for Infection & Immunity, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"2025120415053012000_15.10.e097912.1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S2213-2600(23)00409-5","article-title":"The 2023 UN high-level meeting on tuberculosis: renewing hope, momentum, and commitment to end tuberculosis","volume":"12","author":"Millington","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025120415053012000_15.10.e097912.2","unstructured":"WHO . Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Available: https:\/\/www.who.int\/publications\/i\/item\/9789240061729 accessed 2022-10-27 2022-10-27"},{"key":"2025120415053012000_15.10.e097912.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60570-0"},{"key":"2025120415053012000_15.10.e097912.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m216","article-title":"Current and future treatments for tuberculosis","volume":"368","author":"Lee","year":"2020","journal-title":"BMJ"},{"key":"2025120415053012000_15.10.e097912.5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01054-17","article-title":"Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis","volume":"61","author":"Aarnoutse","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120415053012000_15.10.e097912.6","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.634"},{"key":"2025120415053012000_15.10.e097912.7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir184"},{"key":"2025120415053012000_15.10.e097912.8","first-page":"879","article-title":"U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis","volume":"119","author":"Long","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"2025120415053012000_15.10.e097912.9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jamainternmed.2018.0141","article-title":"Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial","volume":"178","author":"Gopalan","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025120415053012000_15.10.e097912.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"2025120415053012000_15.10.e097912.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-06"},{"key":"2025120415053012000_15.10.e097912.12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky152"},{"key":"2025120415053012000_15.10.e097912.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1843OC"},{"key":"2025120415053012000_15.10.e097912.14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.323"},{"key":"2025120415053012000_15.10.e097912.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-023-08264-2","article-title":"Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial","volume":"23","author":"Feng","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2025120415053012000_15.10.e097912.16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cmi.2021.03.031","article-title":"Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis","volume":"27","author":"Onorato","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025120415053012000_15.10.e097912.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216497"},{"key":"2025120415053012000_15.10.e097912.18","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300054","article-title":"Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis","volume":"2","author":"Jindani","year":"2023","journal-title":"NEJM Evid"},{"key":"2025120415053012000_15.10.e097912.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212537"},{"key":"2025120415053012000_15.10.e097912.20","doi-asserted-by":"crossref","first-page":"e910","DOI":"10.1093\/cid\/ciac585","article-title":"Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin","volume":"76","author":"Sekaggya-Wiltshire","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120415053012000_15.10.e097912.21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/cid\/ciaf003","article-title":"Safety, Efficacy, and Pharmacokinetics of Daily Optimized Doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis","volume":"81","author":"Espinosa-Pereiro","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025120415053012000_15.10.e097912.22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jgar.2022.04.025","article-title":"Advantages of short-course rifamycin-based regimens for latent tuberculosis infection: an updated network meta-analysis","volume":"29","author":"Peng","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2025120415053012000_15.10.e097912.23","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025120415053012000_15.10.e097912.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025120415053012000_15.10.e097912.25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jrsm.1054","article-title":"Automating network meta-analysis","volume":"3","author":"van Valkenhoef","year":"2012","journal-title":"Res Synth Methods"},{"key":"2025120415053012000_15.10.e097912.26","doi-asserted-by":"publisher","DOI":"10.1007\/s11222-011-9281-9"},{"key":"2025120415053012000_15.10.e097912.27","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"2025120415053012000_15.10.e097912.28","doi-asserted-by":"publisher","DOI":"10.2307\/1390675"},{"key":"2025120415053012000_15.10.e097912.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"2025120415053012000_15.10.e097912.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2025120415053012000_15.10.e097912.31","doi-asserted-by":"crossref","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"2025120415053012000_15.10.e097912.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01550-06"},{"key":"2025120415053012000_15.10.e097912.33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis461"},{"key":"2025120415053012000_15.10.e097912.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154778","article-title":"A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis","volume":"11","author":"Conde","year":"2016","journal-title":"PLoS One"},{"key":"2025120415053012000_15.10.e097912.35","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0577"},{"key":"2025120415053012000_15.10.e097912.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2"},{"key":"2025120415053012000_15.10.e097912.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201712-2524OC"},{"key":"2025120415053012000_15.10.e097912.38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/jac\/dkz557","article-title":"Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial","volume":"75","author":"Atwine","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025120415053012000_15.10.e097912.39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5588\/ijtld.19.0063","article-title":"First-line tuberculosis treatment with double-dose rifampicin is well tolerated","volume":"24","author":"Maug","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025120415053012000_15.10.e097912.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400"},{"key":"2025120415053012000_15.10.e097912.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0224-2"},{"key":"2025120415053012000_15.10.e097912.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314210"},{"key":"2025120415053012000_15.10.e097912.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315817"},{"key":"2025120415053012000_15.10.e097912.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"2025120415053012000_15.10.e097912.45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cmi.2020.12.031","article-title":"Patient pathway analysis of tuberculosis diagnostic delay: a multicentre retrospective cohort study in China","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2025120415053012000_15.10.e097912.46","doi-asserted-by":"crossref","first-page":"107230","DOI":"10.1016\/j.ijid.2024.107230","article-title":"Assessing hepatotoxicity in novel and standard short regimens for rifampicin-resistant tuberculosis: Insights from the TB-TRUST and TB-TRUST-plus trials","volume":"148","author":"Song","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025120415053012000_15.10.e097912.47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bcp.16318","article-title":"Drug-induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis","volume":"91","author":"He","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"2025120415053012000_15.10.e097912.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.03.036"},{"key":"2025120415053012000_15.10.e097912.49","unstructured":"WHO . WHO operational handbook on tuberculosis, module 4: treatment - drug-susceptible tuberculosis treatment. 2022. Available: https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1421257\/retrieve [Accessed 24 May 2022]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:06:31Z","timestamp":1764889591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2024-097912"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097912","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}